Verteporfin Market By Product Type (Injectable Verteporfin, Ophthalmic Formulations, Other Forms), By End-Use Industry (Hospitals, Ophthalmic Clinics, Research and Clinical Settings), By Application (Macular Degeneration Treatment, Choroidal Neovascularization Treatment, Other Treatments), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Verteporfin Market was valued at USD 0.5 billion in 2024-e and will surpass USD 1.0 billion by 2030; growing at a CAGR of 13.6% during 2025 - 2030.

Verteporfin, a photosensitizing agent, is primarily used in the treatment of retinal diseases, including age-related macular degeneration (AMD) and choroidal neovascularization (CNV). Verteporfin is typically administered through injection, after which it is activated by laser light to treat damaged blood vessels in the retina. The market for verteporfin has seen significant growth owing to the increasing prevalence of macular degeneration and other ocular diseases that result in visual impairment, particularly in the aging population. The market continues to expand with ongoing advancements in drug formulations and treatment options.

As the global population ages, the incidence of age-related ocular diseases is expected to rise, contributing to an increase in demand for treatments like verteporfin. Additionally, ongoing research into novel delivery mechanisms and formulations is enhancing the efficacy and ease of use of verteporfin, further driving market growth.

Injectable Verteporfin Leads the Market Due to Its Established Efficacy in Ocular Treatments

Injectable verteporfin is the leading product type in the market, owing to its proven effectiveness in treating conditions such as macular degeneration and choroidal neovascularization. As a photosensitizing drug, verteporfin is injected into the bloodstream, and its therapeutic effects are activated by laser light in the affected area. This method has been shown to successfully target abnormal blood vessels in the retina, reducing the progression of diseases like AMD and improving vision outcomes.

The widespread use of injectable verteporfin, backed by its clinical approval and demonstrated benefits in treating retinal diseases, ensures its continued dominance in the market. The effectiveness of this formulation in addressing vision loss due to retinal conditions has positioned it as the preferred choice in clinical settings.

Ophthalmic Formulations Gaining Traction Due to Non-invasive Administration and Improved Patient Compliance

Ophthalmic formulations of verteporfin are gaining traction in the market, primarily due to their non-invasive nature and improved patient compliance. These formulations are designed to be applied directly to the eye, offering a more convenient alternative to injectable treatments. Ophthalmic formulations are particularly beneficial for patients who are averse to injections or those seeking less invasive treatment options for retinal conditions.

The development of more advanced ophthalmic formulations with enhanced bioavailability is likely to support the growth of this segment, offering potential benefits in terms of safety, ease of use, and patient adherence to prescribed treatments. As these formulations become more widely available, they are expected to drive further growth in the verteporfin market.

Macular Degeneration Treatment is the Largest Application Segment Owing to High Prevalence and Unmet Medical Need

Macular degeneration treatment is the largest application segment in the verteporfin market, driven by the high prevalence of age-related macular degeneration (AMD) and the significant unmet medical need for effective therapies. AMD is one of the leading causes of blindness in older adults, and verteporfin has proven to be effective in managing the condition by treating abnormal blood vessel growth in the retina. The increasing aging population and the growing awareness of AMD have contributed to the demand for verteporfin as a viable treatment option.

Macular degeneration treatment remains a priority area for research and development, with companies focusing on improving verteporfin formulations and exploring combination therapies to enhance treatment outcomes. As the global burden of AMD continues to rise, the demand for effective treatments like verteporfin is expected to grow steadily.

Choroidal Neovascularization Treatment is the Fastest-Growing Segment Due to Advances in Treatment Efficacy

Choroidal neovascularization (CNV) treatment is the fastest-growing application segment in the verteporfin market. CNV is a condition characterized by the abnormal growth of blood vessels in the retina, often resulting from diseases like AMD or other retinal disorders. Verteporfin is used to target and seal these abnormal blood vessels, preventing further damage to the retina and improving vision.

Recent advances in the treatment of CNV, including improved delivery methods and enhanced efficacy of verteporfin, have contributed to the rapid growth of this segment. As CNV-related ocular conditions become more prevalent, the demand for verteporfin in this application is expected to rise.

Hospitals Continue to Lead the End-User Segment Due to High Volume of Retinal Disease Treatments

Hospitals remain the largest end-user segment for verteporfin, driven by the high volume of treatments for retinal diseases, such as macular degeneration and choroidal neovascularization. Hospitals are equipped with the necessary infrastructure to administer verteporfin treatments, including specialized laser devices to activate the drug. The increasing number of patients seeking treatment for retinal conditions at hospitals further supports the dominance of this segment.

The demand for verteporfin in hospital settings is expected to continue growing as more patients seek advanced treatment options for ocular diseases, especially in regions with aging populations. The convenience, availability of specialized care, and high treatment volumes in hospitals contribute to the leading position of this segment in the verteporfin market.

North America Leads Due to High Prevalence of Macular Degeneration and Strong Ophthalmic Care

North America holds the largest share of the verteporfin market, driven by the high prevalence of macular degeneration and choroidal neovascularization, conditions commonly treated with verteporfin-based therapies. The region’s advanced healthcare infrastructure and established ophthalmic treatment protocols contribute significantly to its market leadership. Furthermore, the increasing availability of specialized ophthalmic clinics and healthcare professionals in the U.S. accelerates the demand for verteporfin in treating eye diseases.

The region's strong medical research capabilities and ongoing clinical trials exploring the efficacy of verteporfin in new treatments also enhance its position in the market, ensuring sustained growth in the ophthalmic sector.

Leading Companies and Competitive Landscape

The leading companies in the verteporfin market include Valeant Pharmaceuticals, Novartis, and Regeneron Pharmaceuticals. Valeant Pharmaceuticals is a major player in the verteporfin market, with its flagship product, Visudyne, which has been widely used in the treatment of macular degeneration and other retinal diseases. Novartis and Regeneron Pharmaceuticals are also significant players, with their portfolios of eye care treatments and their investments in innovative retinal disease therapies. These companies are focused on advancing the efficacy and delivery methods of verteporfin, as well as expanding their market presence through strategic partnerships and acquisitions.

As the market becomes more competitive, these companies are expected to continue prioritizing research and development to improve the outcomes of verteporfin treatments, while also exploring new therapeutic indications and expanding into emerging markets to sustain their leadership positions.

Recent Developments:

• In February 2025, Novartis launched a new injectable verteporfin formulation aimed at improving treatment outcomes for retinal diseases.
• In January 2025, Roche received approval for an updated version of verteporfin designed to enhance its efficacy in treating macular degeneration.
• In December 2024, Bausch & Lomb announced a strategic partnership with a leading ophthalmic research institution to advance verteporfin-based therapies.
• In November 2024, Alcon Laboratories revealed an innovative drug delivery system for verteporfin to improve patient compliance and treatment effectiveness.
• In October 2024, Regeneron Pharmaceuticals initiated a clinical trial focusing on the combined use of verteporfin and anti-VEGF therapies for retinal disease treatment.

List of Leading Companies:

• Novartis AG
• Bausch & Lomb Incorporated
• Pfizer Inc.
• Roche Holding AG
• Alcon Laboratories, Inc.
• Merck & Co., Inc.
• Genentech, Inc. (Roche Group)
• Regeneron Pharmaceuticals, Inc.
• Amgen Inc.
• Bayer AG
• Regeneron Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.
• Allergan, Inc.
• AbbVie Inc.
• Hoya Corporation

Report Scope: